TTUHSC School of Pharmacy
SOP

Faculty & Staff Details

Photo of Paul Lockman Name: Paul Lockman
Position: Associate Professor, Associate Dean for Outcomes Assessment and Simulation
Email: paul.lockman@ttuhsc.edu
Bio Dr. Lockman earned his B.S. in Nursing from West Texas A&M University (Texas; 1994). He practiced in intensive care, clinical toxicology and emergency medicine, then went on to earn his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center, Graduate School of Biomedical Sciences at the School of Pharmacy (Amarillo; 2003). Dr. Lockman completed his Post-doctoral training through an extramurally funded Fellowship from the Philip Morris External Research Program.

Education:

Postdoctoral Fellowship: Philip Morris External Research Program 2003-2005
Ph.D., Texas Tech University HSC; School of Pharmacy, Pharmaceutical Sciences, 2003
B.S. Nursing, West Texas A&M University, 1994
University of Utah, 1990-92

Research Interests:

Dr. Lockman’s research interests include drug and nutrient transporters at the blood-brain barrier, as well as alterations in the neurovasculature in metastatic brain tumors and chronic nicotine exposure.

    Recent and Current Funding:

  • Department of Defense, U.S. Army Medical Research and Material Command, Congressionally directed medical research programs (2010-2011). Breast Cancer Research Program. #BC096887. Cationic Chemotherapeutics to Penetrate Both the Blood-Brain Barrier and Brain Metastasis of Breast Cancer Cells via the Choline Transporter. Role Principal Investigator.
  • MIcrotransponder; Medical Device Grant (2010-2011) “Feasibility of microstimulation for targeted BBB disruption.” Role Principal Investigator.
  • Department of Defense, U.S. Army Medical Research and Material Command, Congressionally directed medical research programs (2006-2011). Breast Cancer Research Program. # BC050006. Breast Cancer Center of Excellence Award. PI of Center: Pat Steeg at the NCI. Role PI of the sub-project: “Blood-Tumor Barrier Characterization and Nanoparticle Drug Delivery in Brain Metastasis of Breast Cancer”.
  • Minority Health Research and Education Grant program (FY 2008-09). State of Texas Board of Higher Education; Minority Health Research and Education Grant Program. Innovations in Competency Education: Strengthening the Pipeline. Role Co-Principal Investigator; David Fike PhD. Co-Principal Investigator.
  • National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. U19 MH069059-01. (2003 – 2008) “Development of Novel Treatments for Nicotine Addiction.” Linda P. Dwoskin, Principal Investigator. Texas Tech School of Pharmacy Subcontract; Lockman, 2005-2008.
  • Philip Morris External Research Foundation (2003 - 2005). Extramural post-doctoral grant: Brain uptake and neurotransmitter effects of alternative smoking cessation therapeutics.
    Recent Scienticfic Awards:

  • TTUHSC School of Pharmacy, Distinguished Alumni Award; Excellence in Research (2010)
  • Invited Talk; Gordon Research Conference: Barriers of the CNS (2010): Drug delivery to metastatic brain tumors. Colby-Sawyer College, New Hampshire.
  • Invited Talk; Does Chemotherapy Reach Effective Concentrations for the Treatment of Brain Metastases of Breast Cancer? Medical Rounds – London Health Sciences Center. Invited Seminar and Discussion. London Ontario, Canada
  • TTUHSC President’s Young Investigator Research Award (2009)
  • Texas Higher Education Coordinating Board Star Award Finalist (2009)
  • Invited Talk; Breast Cancer Center of Excellence, Invited Panelist and speaker National Breast Cancer Coalition Fund, Annual Advocacy Training Conference, Washington DC.(2009)
  • Invited Talk; Challenges and Opportunities to Deliver Drugs in Brain Metastases of Breast Cancer, Invited Seminar, MD Anderson Houston TX (2009)
  • TTUHSC President’s Excellence in Teaching Award (2008)
  • P3 Teacher of the Year; Texas Tech University HSC, SOP (2008)
  • Invited Talk; Workshop on Drug Delivery in Parkinson’s Disease; Circumventing the Blood-brain barrier (2008):Michael J. Fox Foundation and the Kinetics foundation. San Francisco, CA.
  • American Association of Colleges of Pharmacy; Innovations in Teaching Award (2007)
  • P3 Teacher of the Year; Texas Tech University HSC, SOP (2007)
  • P3 Teaching Team of the Year; Texas Tech University HSC, SOP (2007)
  • Invited Talk; Cancer Biology Seminar Series (2007): Drug delivery across the blood-tumor barrier. MD. Anderson Cancer Center, The University of Texas.
  • P3 Teacher of the Year; Texas Tech University HSC, SOP (2006)
  • P3 Teaching Team of the Year; Texas Tech University HSC, SOP (2006)
  • Invited presentation: 11th Blood-Brain Barrier Disruption Meeting in Portland, OR (2005).
  • P3 Teacher of the Year; Texas Tech University HSC, SOP (2005)
  • P3 Teaching Team of the Year; Texas Tech University HSC, SOP (2005)
  • Designated Fellow, American Foundation of Pharmaceutical Education (2004)
  • P1 Teaching Team of the Year; Texas Tech University HSC, SOP (2004)
  • Nutramax Research Achievement Award (Pharmaceutics) (2003)

Publications:

  • Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim H, Gaasch JA, Palmieri D, Steeg PS, Lockman PR and Smith QR. Brain (2009) Uptake of ANG1005 - a Novel paclitaxel derivative, Through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res; EPUB available
  • Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, and Smith QR. (2010) Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer. Clin Can Res. Accepted
  • Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim H, Gaasch JA, Palmieri D, Steeg PS, Lockman PR and Smith QR. Brain (2009) Uptake of ANG1005 - a Novel paclitaxel derivative, Through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res; 26(11):2486-94
  • Palmieri D, Lockman PR, Thomas F, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar K, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim H, Liewehr DJ, Davis S, Riley J, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon V, Smith QR and Steeg PS. (2009) Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double strand breaks. Clin Cancer Res.15(19):6148-57.
  • Stepp P, Thomas F, Lockman PR, Chen H, Rosengart AJ (2009) In vivo interactions of magnetic nanoparticles with the blood-brain barrier. J Magnetism and Magnetic Materials 321(10):1591-93.
  • Fike D, McCall K, Rahel C, Smith QR and Lockman PR (2009) Achieving equivalent academic performance between campuses in a distance education model through implementation of the keller competency method. AJPE 73(5):88
  • Zhang Z, Lockman PR, Mittapalli RK, Allen DD, Dwoskin LP and Crooks PA (2008) Bis-pyridinium cyclophanes: Novel ligands with high affinity for blood-brain barrier choline transporter. Bioorg Med Chem Lett. 18(20):5622-25.
  • Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce MB, Lockman PR, Manda VK, Ayers JT, Zhang Z, McIntosh JM, Crooks PA and. Bardo MT (2008) "N,N'-Alkane-diyl-bis-3- picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-induced Dopamine Release and Hyperactivity" J Pharm Exp Ther; 326(2):563-76.
  • Lockman PR, Gaasch JA, Borges K, Ehlo A, Smith QR. (2008) Using WebCt to implement a basic science competency education course. (Invited manuscript). AJPE. 72(2):39.
  • Satelli A, Rao P, Gupta P, Lockman P, Srivenugopal S, Rao US. (2008) Varied expression and localization of multiple galectins in different cancer cell lines, Oncol Rep; 19(3):587-94.
  • Lockman PR, Geldenhuys WJ, Manda VC, Thomas FC, Crooks PA, Dwoskin LP, Allen DD. (2008) Carrier mediated transport at the blood-brain barrier for the quaternary ammonium nicotinic receptor antagonist, N, N’-dodecyl-bis-picolinium bromide (bPiDDB). J Pharm Exp Ther. 324(1):244-50.
  • Deuther-Conrad W, Patt JT, Lockman PR, Allen DD, Patt M, Schildan A, Sabri O, Ganapathy V, Brust P, Steinbach J. (2008) In Vivo evaluation of the nicotinic acetylcholine receptor ligand [18]Norchloro-fluor-homoepibatidine (NCFHEB). Europ Neuropsychopharm. 18(3):222-9.
  • Dwoskin LP, Joyce BM, Zheng G, Neugebauer NM, Manda VK, Lockman PR, Papke RL, Bardo MT, Crooks PA. (2007) Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Methylpyridinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochem Pharmacol. 74(8): 1271-82.
  • Palmieri D, Smith QR, Lockman PR, Bronder J, Gril B, Ahmed A, Chambers AF, Weil RJ, Steeg PS. Brain Metastases of Breast Cancer (2007) Breast Dis. (26):139-47
  • Schugar H, Green DE, Bowen ML, Scott LE, Storr L, Böhmerle K, Thomas F, Allen DD, Lockman P, Merkel M, Thompson MH, Orvig C. (2007) Combating Alzheimer's Disease by Designed Multifunctional Molecules for Metal Passivation. Angew. Chem. 46(10): 1716-18
  • Gaasch JA, Geldenhuys WJ, Lockman PR, Allen DD and Van der Schyf CJ, (2007) Voltage gated calcium channels provide and alternate route for iron uptake in neuronal cell cultures. Accepted Neurochem Res. 32(10):1686-93.
  • Gaasch JA, Geldenhuys WJ, Lockman PR, Allen DD and Van der Schyf CJ, (2007)
    Brain iron toxicity: Differential responses of astrocytes, neurons and endothelial cells. Neurochem Res. (7): 1196-208.
  • Lockman PR, Gaasch JA, Van der Schyf CJ, Allen DD. (2006) Chronic nicotine exposure does not alter plasma to brain choline transfer Neurochem Res 31 (4): 503-8.
  • Koziara JM, Lockman PR, Allen DD, Mumper RJ. (2006) The Blood-brain barrier and drug delivery. J Nanosci Nanotech, Invited Review (6): 2712-35.
  • Muldoon LL, Tratnyek P, Jacobs PM, Doolittle ND, Christoforidis GA, Frank J, Lindau M, Lockman PR, Manninger S, Qiang Y, Spence A, Stupp S, Zhang M, Neuwelt E. (2006) Imaging and nanomedicine for diagnosis and therapy in the CNS: Report of the eleventh annual blood-brain barrier disruption consortium meeting. Am J Neuroradiol 27(3) 715-21.
  • Lockman PR, Robbertse G, Geldenhuys WJ, Van der Schyf CJ, Abbruscato TJ, Allen DD. (2005) Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure J Pharm Exp Ther 314(2) 636-42.
  • Geldenhuys WJ, Lockman PR, Philip AE, Miller BL, McCurdy CR, Allen DD. (2005) Inhibition of choline uptake by N-cyclohexylcholine, a high affinity ligand for the choline transporter at the Blood-Brain Barrier. J Drug Targ 13(4) 259-66.
  • Lockman PR, Van der Schyf CJ, Abbruscato TJ, Allen DD. (2005) Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine J Neurochem. 94 (1): 37-44.
  • Geldenhuys WJ, Lockman PR, Nguyen T, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD. (2005) 3D-QSAR study bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter Bioorg Med Chem 13 (13): 4253-61.
  • Cui Z, Lockman PR, Atwood CS, Allen DD, Mumper RJ. (2005) Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. Eur J Pharm Biopharm. 59 (2): 263-72.
  • Lockman PR, Koziara J, Mumper RJ, Allen DD. (2004) Nanoparticle surface charges alter blood-brain barrier integrity and uptake. J Drug Targ. 9-10: 635-41.
  • Lockman PR, McAfee JH, Geldenhuys WJ, Van der Schyf CJ, Allen DD. (2004) Cation transport specificity at the blood-brain barrier. Neurochem Res. 29 (12): 2245-2250.
  • Koziara J, Lockman PR, Allen DD, Mumper RJ. (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Cont Rel. 99: 259-269.
  • Geldenhuys WJ, Lockman PR, McAfee JH, Van der Schyf CJ, Allen DD. (2004) Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorg Med Chem Lett. 14 (12): 3085-3092.
  • Lockman PR, Mumper RJ, Allen DD. (2003) Evaluation of blood-brain barrier thiamine efflux using the in situ rat brain perfusion method. J Neurochem. 86 (3) 637-44.
  • Allen DD, Lockman PR, Roder KE, Dwoskin LP, Crooks PA. (2003) Active transport of high affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J Pharm Exp Ther. 304 (3) 1268-1274.
  • Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, Allen DD. (2003) In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm Res 20 (5) 705-713.
  • Koziara J, Lockman PR, Allen DD, Mumper RJ. (2003) In situ blood-brain barrier transport of nanoparticles. Pharm Res. 20 (11) 1772-78.
  • Lockman PR, Oyewumi M, Koziara J, Roder KE, Mumper RJ, Allen DD. (2003) Brain uptake of thiamine coated nanoparticles. J Cont Rel. 93(3) 271-82.
  • Allen DD, Lockman PR. Invited review. (2003) The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci. 73 (13) 1609-15.
  • Lockman PR (2003) Targeted brain delivery of novel nanoparticles via the blood-brain barrier thiamine transporter. Ph.D. Dissertation. Texas Tech University Health Sciences Center, School of Pharmacy, Department of Pharmaceutical Sciences.
  • Lockman PR, Allen DD. (2002) Invited review. The transport of choline: A review. Drug Dev Ind Pharm. 28 (7) 749 -771.
  • Lockman PR, Mumper RJ, Kahn M, Allen DD. (2002) Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 28 (1), 1-12.
  • Crowe AP, Lockman PR, Abbruscato TJ, Allen DD. (2002) Novel choline transport characteristics in Caco-2 cells. Drug Dev Ind Pharm. 28 (7) 773 - 781.
  • Lockman PR, Roder K Allen DD. (2001) Inhibition of the rat blood-brain barrier choline transporter by manganese chloride. J. Neurochem. 79 (3), 588-94.
  • Lockman PR, Shum S, Allen DD. (2001) Visual toxicity in acute isoniazid overdose. Int J Med Tox. 4 (3), 21.
  • Marchbanks B, Lockman P, Shum S, Beard D. (1999) Trends in ipecac use: a survey of poison center staff. Vet Human Tox. 41 (1), 47-48

    Nicotine interactions at the blood-brain barrier, and or targeted therapies towards nicotine addiction
  • Manda VK, Mittapalli RK, Bohn KA, Adkins CE, and Lockman PR (2010) Nicotine and cotinine increases the brain penetration of saquinavir in rat. J. Neurochem. Accepted.
  • Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR (2010) Chronic exposure to nicotine and saquinqavir decreases endothelial NOTCH-4 expression and disrupts blood-brain barrier integrity. J. Neurochem 115(2):515-25.
  • Geldenhuys WJ, Manda VK, Mittapalli RK, Egbert JA, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD and Lockman PR. (2010) Virtual Screening model development for charged nicotinic antagonists at the blood-brain barrier choline transporter. Bioorg Med Chem Lett 20(3):870-7.
  • Lockman PR, Geldenhuys WJ, Manda VC, Thomas FC, Crooks PA, Dwoskin LP, Allen DD. (2008) Carrier mediated transport at the blood-brain barrier for the quaternary ammonium nicotinic receptor antagonist, N, N’-dodecyl-bis-picolinium bromide (bPiDDB). J Pharm Exp Ther. 324(1):244-50.
  • Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce MB, Lockman PR, Manda VK, Ayers JT, Zhang Z, McIntosh JM, Crooks PA and. Bardo MT (2008) "N,N'-Alkane-diyl-bis-3- picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-induced Dopamine Release and Hyperactivity" J Pharm Exp Ther; 326(2):563-76.

    Competency Education in the Classroom
  • Fike DS, McCall KL, Estes FG, Ndefo UA, Rahel CL, Smith QR and Lockman PR (2010) Improving educational outcomes of Hispanic students in a professional degree program. Equity & Excellence in Education. In Press: 43(4) (TBD)
  • Fike D, McCall K, Rahel C, Smith QR and Lockman PR (2009) Achieving equivalent academic performance between campuses in a distance education model through implementation of the keller competency method. AJPE 73(5):88
  • Lockman PR, Gaasch JA, Borges K, Ehlo A, Smith QR. (2008) Using WebCt to implement a basic science competency education course. (Invited manuscript). AJPE. 72(2):39.
    Published abstracts, and Presentations
    Approximately 100 abstract/presentations at local, national and international meetings.
    Published Abstracts and Presentations:

    Over 100 abstract/presentation at local, national and internaitonal meetings.